MEDCLP Stock Overview
MedinCell S.A., a pharmaceutical company, develops long acting injectables in various therapeutic areas in France.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 5/6 |
Past Performance | 0/6 |
Financial Health | 2/6 |
Dividends | 0/6 |
MedinCell S.A. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | €6.72 |
52 Week High | €9.60 |
52 Week Low | €5.80 |
Beta | 1 |
1 Month Change | 0% |
3 Month Change | n/a |
1 Year Change | 28.98% |
3 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | 26.55% |
Recent News & Updates
Recent updates
Shareholder Returns
MEDCLP | GB Pharmaceuticals | GB Market | |
---|---|---|---|
7D | 0% | 1.8% | 2.0% |
1Y | 29.0% | 6.6% | 4.5% |
Return vs Industry: MEDCLP exceeded the UK Pharmaceuticals industry which returned -7.1% over the past year.
Return vs Market: MEDCLP exceeded the UK Market which returned -2.4% over the past year.
Price Volatility
MEDCLP volatility | |
---|---|
MEDCLP Average Weekly Movement | n/a |
Pharmaceuticals Industry Average Movement | 7.8% |
Market Average Movement | 4.8% |
10% most volatile stocks in GB Market | 11.4% |
10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: MEDCLP has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine MEDCLP's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2003 | 131 | Christophe Douat | www.medincell.com |
MedinCell S.A., a pharmaceutical company, develops long acting injectables in various therapeutic areas in France. It develops solutions based on BEPO, a long-acting injectable technology. The company’s products in development include mdc-IRM, a risperidone extended-release injectable suspension for use in the treatment of schizophrenia in adults; mdc-CWM, a sustained-release formulation of celecoxib in Phase III trials for use in the treatment of reduction of postoperative pain and inflammation; and mdc-TJK, a subcutaneous injection that is in Phase III clinical trials for use in the treatment of schizophrenia.
MedinCell S.A. Fundamentals Summary
MEDCLP fundamental statistics | |
---|---|
Market cap | €188.34m |
Earnings (TTM) | -€32.01m |
Revenue (TTM) | €13.66m |
13.8x
P/S Ratio-5.9x
P/E RatioIs MEDCLP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
MEDCLP income statement (TTM) | |
---|---|
Revenue | €13.66m |
Cost of Revenue | €0 |
Gross Profit | €13.66m |
Other Expenses | €45.67m |
Earnings | -€32.01m |
Last Reported Earnings
Mar 31, 2023
Next Earnings Date
Dec 06, 2023
Earnings per share (EPS) | -1.11 |
Gross Margin | 100.00% |
Net Profit Margin | -234.42% |
Debt/Equity Ratio | -128.9% |
How did MEDCLP perform over the long term?
See historical performance and comparison